NxClinical 4.1 is a unique software solution for integration of copy number, sequence variants, and allelic changes obtained from microarray and NGS technologies. NxClinical 4.1 allows combined analysis and interpretation of all genomic variants on a single, platform agnostic system.
BioDiscovery, a leader in copy number analysis software, created a new tailored software solution (Nexus Express for OncoScan) for copy number detection and downstream analysis for the OncoScan™ CNV Assay. The assay plus software solution allows researchers performing solid tumor analysis a high-quality, complete, end-to-end solution from raw data to discovery for difficult FFPE samples.
BioDiscovery announced today an agreement with Be Creative Lab in Beijing, China to be the exclusive reseller and distributor of BioDiscovery products in China.
BioDiscovery launches NxClinical 4.0, a unique system allowing analysis and interpretation of CNV, SNV, and AOH from a single NGS assay.
The new features in Nexus Copy Number 9.0 really enhance the usability of WES, WGS, targeted panels and low-pass sequencing for copy number analysis.
GENALICE and BioDiscovery announce a co-marketing partnership to offer their products together as a turn-key end-to-end solution for the use of next-generation sequencing (NGS) data to interpret genomes.
NxClinical 3.0 will be launched during the ASHG 2016 Meeting, October 18-21 in Vancouver, BC, Canada
Ambry Genetics selects BioDiscovery’s NxClinical software for analysis, management, and reporting of copy number events in its clinical genomics workflow.
Illumina Selects BioDiscovery’s NxClinical Software for Data Visualization, Management and Interpretation for its CytoSeq ™ assay, an NGS-based Solution for Detection of CNVs, AOH, and SNVs
Nexus Copy Number 8.0 is derivation of copy number from NGS results. BAM (pooled reference), detects copy number from WES, WGS, and targeted NGS panels.